Role of GPs
GPs play a key role in ensuring that program participants progress through the screening pathway. GPs deliver clinically appropriate advice, services, treatment and care, and provide data on participants and their outcomes to the Program Register.
For your patients, you are asked to:
- encourage those who are sent a screening test and for whom the test is clinically relevant, to participate.
- assess those with a positive result and refer them for further examination as clinically indicated, for example a colonoscopy.
- indicate whether a patient referred for colonoscopy is a Program participant to assist with reporting to the Program Register. Program stickers are available by calling the Information Line on 1800 118 868.
- notify the Program Register of referral/non referral for colonoscopy or other bowel examination for participants with a positive result. This can be done by returning the Program’s GP Assessment Form by fax, post or electronically. Provision of information will attract a payment.
- inform patients at average risk, or slightly above, that the NHMRC Guidelines recommend screening at least once every two years from the age of 50.
- manage patients identified as being at increased risk of bowel cancer in accordance with the National Health and Medical Research Council (NHMRC) Guidelines.
- manage patients (of any age) with symptoms in accordance with the NHMRC Guidelines, in recognition that bowel cancer can occur at any age.
Role of practice nurses
Practice nurses have an important role to play in encouraging and supporting patients to participate in the Program. Nurses can act as connectors between patients and their GP as both an advocate and interpreter.
To encourage your patients to screen, you can:
- Promote the Program in your practice;
- Undertake a screening audit of practice records;
- Talk to your patients aged 49 to 74 about screening;
- Send a letter to 49 year olds to encourage participation;
- Find out when patients will receive a kit, and if appropriate encourage participation;
- Demonstrate to patients how to use a bowel screening test kit;
- Assist with completing forms for Program participants; and
- Refer patients (of any age) with symptoms, bowel disease or family history to a GP in recognition that bowel cancer can occur at any age.
The Australian Primary Healthcare Nurses Association, in partnership with the Cancer Council WA and funded by the Australian Government Department of Health, has developed resources and training on the Program for nurses working in general practice.
How can general practices support participation?Research consistently demonstrates that a recommendation from a primary care provider to screen for bowel cancer is an important motivator for participation. General practices can encourage their patients to participate by:
- Displaying brochures, flyers and posters – Order Program Resources
- Talking to patients aged 50-74 years about bowel cancer screening - Download Clinical Resources
or check when an individual will get a kit
- Demonstrating how to use a kit. Demonstration kits can be ordered by emailing NBCSP@health.gov.au
- Sending a letter to 49 year old patients to encourage participation - Download a template letter
- Knowing the Program – this series of short videos provides a simplified approach to the NBCSP covering the following topics: What is screening, Classification of risk, Referral to colonoscopy and Case studies. For practice nurses this Webinar is a one-hour online seminar on bowel cancer, screening and how nurses working in general practice can approach bowel screening with patients.
Send a letter to your 49 year old patients
There is strong evidence that a letter signed by a person’s GP endorsing FOBT is an effective method to increase participation in bowel cancer screening.
GPs can use this template letter to recommend screening to patients outside of regular consultations. Currently, 50 year olds have the lowest participation rate in the Program. It is recommended that general practices send the letter to 49 year old patients to encourage them to do the test when they receive it in the mail around their 50th birthday.
You can delete the icons from the letter before you send it if you prefer.
Health service providers have obligations under the Privacy Act 1988 and relevant State and Territory privacy laws when handling personal information. The template letter has been drafted to comply with relevant privacy obligations. If you alter the letter before you send it to your patients, you should consider whether it still meets your privacy obligations. If you have any queries about your privacy obligations please email the Office of the Australian Information Commissioner or call 1300 363 992.
Program evidence base
The National Health and Medical Research Council (NHMRC) Guidelines recommend FOBT screening at least every two years for people over the age of 50 who are at, or slightly above, average risk for bowel cancer (about 98% of the population).
- In line with this, the Program is expanding in stages so that by 2020 all eligible Australians aged 50-74 years will be invited to participate every two years.
- The direct mail model used by the Program is the most common model internationally and the most effective recruitment method for a population based bowel screening program.
- A 2014 study by the Australian Institute of Health and Welfare found that:
- Program invitees had 15% less risk of dying from bowel cancer, and were more likely to have less-advanced bowel cancers when diagnosed, than non-invitees.
- the immunochemical FOBT used in the Program has a high degree of accuracy (estimated 83% sensitivity and 93% specificity).
- A July 2015 Healthpact report found that the immunochemical FOBT, as is used in the Program, is the best performing screening test for use in population screening.
- In 2014, 7% of participants (34, 378 people) returned a positive screening test, and of these 73% (25,242 people) had a diagnostic assessment recorded by the end of 2015. Of assessments occurring in 2014, there were:
- 181 (0.7%) confirmed cancers;
- 638 (2.4%) suspected cancers; and
- 3655 (14%) adenomas detected.
For more data on the Program see the 2016 Program Monitoring Report